journal article·2024-08-22Open access

Chitosan-Stabilized Selenium Nanoparticles Alleviate High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease (NAFLD) by Modulating the Gut Barrier Function and Microbiota

Yuhang Luo, Shujiang Peng, Jintao Cheng, Hongli Yang, Lin Lin, Guiling Yang, Yuanxiang Jin, Qingchi Wang, Zhengshun Wen

Abstract

Low molecular weight chitosan selenium nanoparticles (LCS-SeNPs), a biologically active compound derived from selenium polysaccharides, have demonstrated potential in addressing obesity. However, the mechanism through which LCS-SeNPs alleviate high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) remains unclear. Our results elucidated that LCS-SeNPs significantly inhibited fat accumulation and markedly improved the intestinal barrier by increasing mucus secretion from goblet cells. Moreover, LCS-SeNPs reshaped intestinal flora composition by increasing the abundance of mucus-associated microbiota (Bifidobacterium, Akkermansia, and Muribaculaceae_unclassified) and decreasing the abundance of obesity-contributed bacterium (Anaerotruncus, Lachnoclostridium, and Proteus). The modulation of intestinal microbiota by LCS-SeNPs influenced several metabolic pathways, including bile acid secretion, purine metabolites, and tryptophan derivation. Meanwhile, glycocholic acid and tauro-beta-muricholic acid were significantly reduced in the LCS-SeNP group. Our study suggests the crucial role of intestinal microbiota composition and metabolism, providing a new theoretical foundation for utilizing selenium polysaccharides in the intervention of HFD-induced NAFLD.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Liver Disease Diagnosis and Treatment · Gut microbiota and health · Diet, Metabolism, and Disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Food and Pharmacy, Zhejiang Ocean University, Zhoushan 316022, China

Xianghu Laboratory, Hangzhou 311231, China

College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou 310032, China

Funding

Department of Science and Technology of Zhejiang Province · Key Laboratory for Efficient Development and Utilization of Deep Sea Fisheries Resources of Zhejiang Province · Ministry of Science and Technology of the People’s Republic of China · Bureau of Science and Technology of Zhoushan · Xianghu Laboratory · Department of Science and Technology of Shandong Province

References (79)

Show source-provided references
1. Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis10.1016/j.cmet.2023.07.011 ↗
2. Non-alcoholic fatty liver disease10.1016/S0140-6736(20)32511-3 ↗
3. The global NAFLD epidemic10.1038/nrgastro.2013.171 ↗
4. Interactions between commensal intestinal bacteria and the immune system10.1038/nri1373 ↗
5. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease10.1111/bph.14095 ↗
6. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): Focusing on the gut–liver axis10.1080/10408398.2021.1966738 ↗
7. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus10.1038/s41574-021-00507-z ↗
8. Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats10.1039/D2FO01009G ↗
9. Research progress on the biological activities of selenium polysaccharides10.1039/C9FO02026H ↗
10. Protective effect of selenium-polysaccharides from the mycelia of Coprinus comatus on alloxan-induced oxidative stress in mice10.1016/j.foodchem.2009.03.073 ↗
11. Selenium-containing polysaccharides from Ziyang green tea ameliorate high-fructose diet induced insulin resistance and hepatic oxidative stress in mice10.1039/C5FO00557D ↗
12. Selenylation modification can enhance immune-enhancing activity of Chuanminshen violaceum polysaccharide10.1016/j.carbpol.2016.07.055 ↗
13. Selenium enrichment of lactic acid bacteria and bifidobacteria: A functional food perspective10.1016/j.tifs.2014.07.006 ↗
14. Gut Microbiome and Metabolomics Study of Selenium-Enriched Kiwifruit Regulating Hyperlipidemia in Mice Induced by a High-Fat Diet10.1021/acs.jafc.3c00108 ↗
15. Chen, Y., Liu, Y., Dong, Q., Xu, C., Deng, S., Kang, Y., Fan, M., and Li, L. (2023). Application of functionalized chitosan in food: A review. Int. J. Biol. Macromol., 235.10.1016/j.ijbiomac.2023.123716 ↗
16. Chitosan: Structural modification, biological activity and application10.1016/j.ijbiomac.2020.09.042 ↗
17. Low molecular weight chitosan oligosaccharides (LMW-COSs) prevent obesity-related metabolic abnormalities in association with the modification of gut microbiota in high-fat diet (HFD)-fed mice10.1039/D0FO01871F ↗
18. A propitious role of marine sourced polysaccharides: Drug delivery and biomedical applications10.1016/j.carbpol.2022.120448 ↗
19. Zhang, G., Zhang, M., Pei, Y., Qian, K., Xie, J., Huang, Q., Liu, S., Xue, N., Zu, Y., and Wang, H. (2023). Enhancing stability of liposomes using high molecular weight chitosan to promote antioxidative stress effects and lipid-lowering activity of encapsulated lutein in vivo and in vitro. Int. J. Biol. Macromol., 253.10.1016/j.ijbiomac.2023.126564 ↗
20. N-trimethyl chitosan coated targeting nanoparticles improve the oral bioavailability and antioxidant activity of vitexin10.1016/j.carbpol.2022.119273 ↗
21. Peng, S.-J., Ye, D.-T., Zheng, J., Xue, Y.-R., Lin, L., Zhao, Y.-D., Miao, W.-H., Song, Y., Wen, Z.-S., and Zheng, B. (2022). Synthesis, characterization of low molecular weight chitosan selenium nanoparticles and its effect on dss-induced ulcerative colitis in mice. Int. J. Mol. Sci., 23.10.3390/ijms232415527 ↗
22. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: Distinct clinicopathologic meanings10.1002/hep.24127 ↗
23. Noninvasive evaluation of NAFLD10.1038/nrgastro.2013.175 ↗
24. Long-term follow-up of patients with NAFLD and elevated liver enzymes10.1002/hep.21327 ↗
25. Oat bran prevents high-fat-diet induced muscular dysfunction, systemic inflammation and oxidative stress through reconstructing gut microbiome and circulating metabolome10.1016/j.foodres.2023.113127 ↗
26. Intestinal barrier function: Molecular regulation and disease pathogenesis10.1016/j.jaci.2009.05.038 ↗
27. Phlorizin ameliorates obesity-associated endotoxemia and insulin resistance in high-fat diet-fed mice by targeting the gut microbiota and intestinal barrier integrity10.1080/19490976.2020.1842990 ↗
28. Chitosan oligosaccharide mitigates kidney injury in prediabetic rats by improving intestinal barrier and renal autophagy10.1016/j.carbpol.2022.119405 ↗
29. Heptamethoxyflavone Alleviates Metabolic Syndrome in High-Fat Diet-Fed Mice by Regulating the Composition, Function, and Metabolism of Gut Microbiota10.1021/acs.jafc.3c01881 ↗
30. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity10.1073/pnas.1219451110 ↗
31. Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice10.1038/s41564-021-00880-5 ↗
32. Akkermansia muciniphila inhibits nonalcoholic steatohepatitis by orchestrating TLR2-activated γδT17 cell and macrophage polarization10.1080/19490976.2023.2221485 ↗
33. Genus unclassified_Muribaculaceae and microbiota-derived butyrate and indole-3-propionic acid are involved in benzene-induced hematopoietic injury in mice10.1016/j.chemosphere.2022.137499 ↗
34. Effects of fermented wheat bran and yeast culture on growth performance, immunity, and intestinal microflora in growing-finishing pigs10.1093/jas/skab308 ↗
35. Dietary Chito-oligosaccharides Improve Intestinal Immunity via Regulating Microbiota and Th17/Treg Balance-Related Immune Signaling in Piglets Challenged by Enterotoxigenic E. coli10.1021/acs.jafc.1c06029 ↗
36. Yoon, S.J., Yu, J.S., Min, B.H., Gupta, H., Won, S.-M., Park, H.J., Han, S.H., Kim, B.-Y., Kim, K.H., and Kim, B.K. (2023). Bifidobacterium-derived short-chain fatty acids and indole compounds attenuate nonalcoholic fatty liver disease by modulating gut-liver axis. Front. Microbiol., 14.10.3389/fmicb.2023.1129904 ↗
37. Procyanidin B2 prevents dyslipidemia via modulation of gut microbiome and related metabolites in high-fat diet fed mice10.1016/j.jff.2020.104285 ↗
38. Polysaccharide from Ziyang Selenium-Enriched Green Tea Prevents Obesity and Promotes Adipose Thermogenesis via Modulating the Gut Microbiota10.1021/acs.jafc.3c04193 ↗
39. Yang, L., Wang, Y., Zheng, G., Li, Z., and Mei, J. (2023). Resveratrol-loaded selenium/chitosan nano-flowers alleviate glucolipid metabolism disorder-associated cognitive impairment in Alzheimer's disease. Int. J. Biol. Macromol., 239.10.1016/j.ijbiomac.2023.124316 ↗
40. Ran, Q., Gan, Q., Zhu, Y., Song, L., Shen, L., Duan, X., Zhu, X., and Huang, W. (2024). Mechanism insights into the pleiotropic effects of nobiletin as a potential therapeutic agent on non-alcoholic fatty liver disease (NAFLD). Biomed. Pharmacother., 173.10.1016/j.biopha.2024.116322 ↗
41. Smilax China L. polysaccharide prevents HFD induced-NAFLD by regulating hepatic fat metabolism and gut microbiota10.1016/j.phymed.2024.155478 ↗
42. AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome10.1016/j.cmet.2009.03.012 ↗
43. CD36 plays a negative role in the regulation of lipophagy in hepatocytes through an AMPK-dependent pathway10.1194/jlr.M090969 ↗
44. Nano-selenium supplements in high-fat diets relieve hepatopancreas injury and improve survival of grass carp Ctenopharyngodon Idella by reducing lipid deposition10.1016/j.aquaculture.2021.736580 ↗
45. Tao, W., Sun, W., Liu, L., Wang, G., Xiao, Z., Pei, X., and Wang, M. (2019). Chitosan Oligosaccharide Attenuates Nonalcoholic Fatty Liver Disease Induced by High Fat Diet through Reducing Lipid Accumulation, Inflammation and Oxidative Stress in C57BL/6 Mice. Mar. Drugs, 17.10.3390/md17110645 ↗
46. (-)-Epicatechin protects the intestinal barrier from high fat diet-induced permeabilization: Implications for steatosis and insulin resistance10.1016/j.redox.2017.11.002 ↗
47. New targets for NAFLD10.1016/j.jhepr.2021.100346 ↗
48. Biomimetic MicroRNAs-Selenium-Nanocomposites for Targeted and Combined Hyperlipidemia Therapy10.1002/adhm.202400064 ↗
49. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators10.1136/gut.2007.140806 ↗
50. Occludin: Structure, function and regulation10.1016/j.addr.2005.01.009 ↗
51. Intestinal Barrier Function–Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota10.1021/acs.jafc.9b00080 ↗
52. The role of MUC2 mucin in intestinal homeostasis and the impact of dietary components on MUC2 expression10.1016/j.ijbiomac.2020.07.191 ↗
53. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus10.1073/pnas.0808722106 ↗
54. Prebiotic oligofructose protects against high-fat diet-induced obesity by changing the gut microbiota, intestinal mucus production, glycosylation and secretion10.1080/19490976.2022.2152307 ↗
55. Gut microbiota in human metabolic health and disease10.1038/s41579-020-0433-9 ↗
56. Qian, M., Lyu, Q., Liu, Y., Hu, H., Wang, S., Pan, C., Duan, X., Gao, Y., Qi, L.-W., and Liu, W. (2019). Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice. Mar. Drugs, 17.10.3390/md17070391 ↗
57. Ameliorating the effect and mechanism of chitosan oligosaccharide on nonalcoholic fatty liver disease in mice10.1039/D3FO03745B ↗
58. Selenium-Enriched Probiotic Alleviates Western Diet-Induced Non-alcoholic Fatty Liver Disease in Rats via Modulation of Autophagy Through AMPK/SIRT-1 Pathway10.1007/s12011-022-03247-x ↗
59. Akkermansia muciniphila: Paradigm for next-generation beneficial microorganisms10.1038/s41575-022-00631-9 ↗
60. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: A proof-of-concept exploratory study10.1038/s41591-019-0495-2 ↗
61. Mucin degrader Akkermansia muciniphila accelerates intestinal stem cell-mediated epithelial development10.1080/19490976.2021.1892441 ↗
62. The role of gut vascular barrier in experimental alcoholic liver disease and A. muciniphila supplementation10.1080/19490976.2020.1851986 ↗
63. Bifidobacterium adolescentis and Lactobacillus rhamnosus alleviate non-alcoholic fatty liver disease induced by a high-fat, high-cholesterol diet through modulation of different gut microbiota-dependent pathways10.1039/C9FO02905B ↗
64. Ferulic acid improves intestinal barrier function through altering gut microbiota composition in high-fat diet-induced mice10.1007/s00394-022-02927-7 ↗
65. Preventive Effects of Apple Polyphenol Extract on High-Fat-Diet-Induced Hepatic Steatosis Are Related to the Regulation of Hepatic Lipid Metabolism, Autophagy, and Gut Microbiota in Aged Mice10.1021/acs.jafc.3c00596 ↗
66. Probiotics improve gut microbiota dysbiosis in obese mice fed a high-fat or high-sucrose diet10.1016/j.nut.2018.10.002 ↗
67. Flavonoids from Whole-Grain Oat Alleviated High-Fat Diet-Induced Hyperlipidemia via Regulating Bile Acid Metabolism and Gut Microbiota in Mice10.1021/acs.jafc.1c01813 ↗
68. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD10.1136/gutjnl-2017-314307 ↗
69. Role of Bile Acids in Metabolic Control10.1016/j.tem.2017.11.002 ↗
70. Longitudinal Multi-omics Reveals Subset-Specific Mechanisms Underlying Irritable Bowel Syndrome10.1016/j.cell.2020.08.007 ↗
71. Inhibition of microbial deconjugation of micellar bile acids protects against intestinal permeability and liver injury10.1126/sciadv.abo2794 ↗
72. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet–fed mice10.1126/scitranslmed.aaf4823 ↗
73. Dietary acetic acid suppress high-fat diet-induced obesity in mice by altering taurine conjugated bile acids metabolism10.1016/j.crfs.2022.10.021 ↗
74. Metabolomic signatures for liver tissue and cecum contents in high-fat diet-induced obese mice based on UHPLC-Q-TOF/MS10.1186/s12986-021-00595-8 ↗
75. Li, H., Xi, Y., Xin, X., Tian, H., and Hu, Y. (2020). Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota–bile acid–farnesoid X receptor axis. Biomed. Pharmacother., 124.10.1016/j.biopha.2020.109915 ↗
76. Song, Z., Cai, Y., Lao, X., Wang, X., Lin, X., Cui, Y., Kalavagunta, P.K., Liao, J., Jin, L., and Shang, J. (2019). Taxonomic profiling and populational patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome. Microbiome, 7.10.1186/s40168-019-0628-3 ↗
77. Verbascoside exerts an anti-atherosclerotic effect by regulating liver glycerophospholipid metabolism10.1016/j.fshw.2023.03.035 ↗
78. Analysis of serum lysophosphatidylethanolamine levels in patients with non-alcoholic fatty liver disease by liquid chromatography-tandem mass spectrometry10.1007/s00216-020-02996-9 ↗
79. Phenolamide extract of apricot bee pollen alleviates glucolipid metabolic disorders and modulates the gut microbiota and metabolites in high-fat diet-induced obese mice10.1039/D3FO01016C ↗